
Michelson Diagnostics Ltd., Kent, United Kingdom
Diagnostic imaging company focused on the diagnosis and treatment-management of a variety of skin conditions. Utilizing multi-beam optical coherence tomography (“OCT”), the VivoSight device enables dermatologists to capture real-time, non-invasive, continuous, high-resolution images of the sub-surface of the skin.
Private investment round to fund the European market launch of VivoSight Dx, Michelson’s 2nd generation OCT imaging device and further explore the use of VivoSight and Dynamic OCT software in the assessment of burns, wounds and aesthetic dermatology.
Smith & Nephew, Octopus Ventures, Kent County Council and angel investors
£2,500,000 Series B
Acted as financial advisor to the Board of Directors and management
- Approached selected corporate and financial investors.
- Structured financing round to align interests of incoming corporate investor with those of existing financial and angel investors.
- Spearheaded negotiation on behalf of the Company with Smith & Nephew to complete the transaction.